Most melanoma occurs on the skin where it can be visible to the person for some period of time before a clinical diagnosis is made. Consumers therefore have a highly valuable, although underutilized, role in the early detection of melanoma.
It is our aim to improve consumers’ effectiveness in the timely detection of suspicious lesions and, in so doing, to ultimately reduce the morbidity, mortality, cost and suffering associated with advanced disease.
The CRE Investigators are active in international melanoma early detection efforts, and will build on this experience and expertise over the next five years to:
Achieve earlier and better technology-facilitated diagnosis of melanoma, reducing late-stage presentations.
Support consumers in the active and effective self-detection of their suspicious pigmented lesions thus reducing delays in the follow-up and management of these lesions.
Significantly improve standard of care and treatment pathways for patients with suspicious pigmented lesions, enhance access to best standard of care regardless of location or mobility.
Make a significant contribution to clinical practice in melanoma early detection, to improve consistency of standards of care across states/territories.